Holocene Advisors
PTCT icon

Holocene Advisors’s PTC Therapeutics PTCT Stock Holding History

Holocene Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-242,623
Closed -$11.8M – 833
2023
Q1 		$11.8M Buy
+242,623
New +$11.1M 0.06% 229
2020
Q1 		– Sell
-252,177
Closed -$12.1M – 798
2019
Q4 		$12.1M Buy
+252,177
New +$10.7M 0.11% 146

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Holocene Advisors's PTCT Position: Q2 2023 in Review

Holocene Advisors sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 242,623 shares — an estimated $11.8M sold.

Holocene Advisors first reported a position in PTCT in Q4 2019 and held it in 2 quarters. The position peaked at $12.1M in Q4 2019. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

  • Holocene Advisors reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Holocene Advisors sold 242,623 PTC Therapeutics shares in Q2 2023, an estimated $11.8M.
  • Holocene Advisors first reported a position in PTC Therapeutics in Q4 2019 and held it in 2 quarters.
  • Holocene Advisors's PTC Therapeutics position peaked at $12.1M in Q4 2019.
  • 204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Holocene Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.